It forecast an adjusted core loss of 30 million to 40 million Swiss francs ($33.4 million to $44.5 million) in 2023, compared to the previous range of 20-40 million.
DocMorris also cut its 2023 external revenue outlook, expecting a high single-digit percentage decline in local currency, from a previously expected mid-single-digit drop.
Its external revenue fell by 5.8% to 256 million Swiss francs in the third quarter, below the 262 million francs expected by analysts polled by the company.
Redcare Pharmacy (RDC.DE) earlier in October said its third quarter sales rose by two thirds, aided by double-digit growth in sales of non-prescription products.
But analysts said DocMorris had weighed on the wider sector and Redcare Pharmacy's shares fell around 3% on Thursday.
Persons:
DocMorris, Redcare, Baader Helvea, Pharmacy's, Tristan Veyet, Milla Nissi, Barbara Lewis
Organizations:
DocMorris, Thomson
Locations:
Swiss, Germany, Gdansk